Every Form 4 that Senti Biosciences Holdings, Inc. (SNTI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SNTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNTI filings page.
Senti Biosciences Holdings, Inc. (SNTI) reported that 19,953 common shares were withheld by the issuer from Kanya Rajangam, the issuer’s Pres. & Chief Med. & Dev. Off., on October 21, 2026, to satisfy income tax withholding and remittance obligations tied to net settlement of certain time-based restricted stock unit awards. The withholding was not an open-market sale. Rajangam directly held 54,890 common shares following the transaction.
Senti Biosciences Holdings, Inc. (SNTI) CEO and director Timothy K. Lu reported that 157,312 common shares were withheld by the issuer on October 21, 2026, to satisfy income tax withholding and remittance obligations in connection with net settlement of certain time-based restricted stock unit awards. The shares were not an open-market sale. Lu directly held 482,271 shares afterward. Separate indirect holdings are listed as 52,839 shares held by his spouse and 52,839 shares held by Luminen Services, LLC, trustee of the Luminen Trust; Lu is the trust’s settlor and disclaims Section 16 beneficial ownership except to the extent of his pecuniary interest, if any. No Rule 10b5-1 plan is reported.
Senti Biosciences executive Kanya Rajangam reported a routine tax-related share disposition. On this filing, 10,757 shares of common stock were withheld by the company to cover income tax obligations tied to vested restricted stock units, and not sold on the open market. After this withholding, Rajangam directly holds 74,843 common shares.
Senti Biosciences CEO Timothy K. Lu reported a tax-related share disposition. On the net settlement of time-based restricted stock units, 80,666 shares of common stock were withheld by the company to cover income tax obligations and remittance, which the filing states is not an open market sale. After this withholding, Lu directly holds 639,583 common shares, and the filing also notes 52,839 shares held indirectly, including through the Luminen Trust, where he disclaims beneficial ownership except for any pecuniary interest.
Senti Biosciences officer reports tax share withholding from RSU settlement. On 02/02/2026, Pres. & Chief Med. & Dev. Officer Kanya Rajangam had 1,384 shares of Senti Biosciences common stock withheld at a price of $0 per share to cover income tax obligations on vested restricted stock units.
These shares were withheld by the company and the transaction did not involve an open market sale. Following this tax-related withholding, Rajangam directly beneficially owns 85,600 shares of Senti Biosciences common stock.
Senti Biosciences CEO Timothy K. Lu reported a routine tax-related share withholding. On February 2, 2026, the company withheld 4,191 shares of common stock to cover income tax obligations tied to vested restricted stock units, which was not an open market sale.
After this withholding, Lu directly beneficially owned 720,249 shares of common stock. The filing also lists 52,839 shares held indirectly by his spouse and another 52,839 shares held by Luminen Services, LLC as trustee of the Luminen Trust, for which Lu disclaims beneficial ownership except for any pecuniary interest.